1076230-22-2

Basic information

• Product Name: (3S,4S)-3-(4-fluoro-2-methylphenyl)piperidine-4-carboxylic acid [(S)-1-(3,5-bistrifluoromethylphenyl)ethyl]methylamide hydrochloride
• Synonyms: (3S,4S)-3-(4-fluoro-2-methylphenyl)piperidine-4-carboxylic acid [(S)-1-(3,5-bistrifluoromethylphenyl)ethyl]methylamide hydrochloride
• CAS NO: 1076230-22-2
• Molecular Weight: 526.925
• Mol File: 1076230-22-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (3S,4S)-3-(4-fluoro-2-methylphenyl)piperidine-4-carboxylic acid [(S)-1-(3,5-bistrifluoromethylphenyl)ethyl]methylamide hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (3S,4S)-3-(4-fluoro-2-methylphenyl)piperidine-4-carboxylic acid [(S)-1-(3,5-bistrifluoromethylphenyl)ethyl]methylamide hydrochloride(1076230-22-2)
• EPA Substance Registry System: (3S,4S)-3-(4-fluoro-2-methylphenyl)piperidine-4-carboxylic acid [(S)-1-(3,5-bistrifluoromethylphenyl)ethyl]methylamide hydrochloride(1076230-22-2)

Safety Data

• Hazardous Substances Data: 1076230-22-2(Hazardous Substances Data)

Upstream product

• 30071-93-3 3,5-bis(trifluoromethyl)phenyl methyl ketone 
• 497843-21-7 1-benzyl-5-(trifluoromethanesulfonoyloxy)-3,6-dihydro-2H-pyridine-4-carboxylic acid ethyl ester 
• 52763-21-0 ethyl 1-benzyl-3-oxopiperidine-4-carboxylate hydrochloride 

Downstream Products

• 1076228-22-2 (3S,4S)-1-[amino(oxo)acetyl]-N-((1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl)-3-(4-fluoro-2-methylphenyl)-N-methylpiperidine-4-carboxamide 

Relevant articles and documents

NK1 RECEPTOR ANTAGONIST

A problem of the present invention is to provide a new compound which has NK1 receptor antagonist activity, and thus is useful for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting. A compound represented by the formula (I): wherein W represents a fluorine atom and the like, ring A represents a cycloalkyl and the like, X1 represents CH or N, R represents methyl and the like, Y represents 0 to 2, U1, U2 and U3 each independently represents a single bond and the like, or a pharmaceutically acceptable salt thereof. The compounds of the present invention or pharmaceutically acceptable salts thereof have an excellent NK1 receptor antagonist activity, and thus are also useful as an agent for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting.